EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity
EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity
"The reduction in liver fat observed preclinically with our miniature, subdermal exenatide implant provides further support that the NanoPortal implant technology continues to hold great potential as a highly differentiated treatment option for the treatment of obesity and chronic weight management as well as related metabolic disorders...Our first clinical study, LIBERATE-1, is anticipated to start in the fourth quarter of 2024 with results in 2025," said Adam Mendelsohn, Vivani President and CEO.On Wednesday, Vivani Medical, Inc. (NASDAQ:VANI) reported preclinical liver fat results with its exenatide implant for obese patients.
周三，维瓦尼医疗公司（美国纳斯达克证券交易所股票代码：VANI）报道称，其埃塞那肽植入物在肥胖患者身上能够改善肝脂肪临床试验结果。
Exenatide is sold by AstraZeneca Plc (NASDAQ:AZN) under the brand names Byetta and Bydureon BCise to treat type 2 diabetes.
阿斯利康有限公司（纳斯达克证券交易所股票代码：AZN）销售埃塞那肽的品牌为Byetta和Bydureon BCise, 用于治疗2型糖尿病。
Also Read: EXCLUSIVE: Vivani Medical Highlights Weight Loss Data For GLP-1 Implant Supporting Potential Veterinary Use.
此外读者还可阅读专题报道：维瓦尼医疗公司重点介绍了GLP-1植入物的减重数据，还支持潜在兽医用途。
"The reduction in liver fat observed preclinically with our miniature, subdermal exenatide implant provides further support that the NanoPortal implant technology continues to hold great potential as a highly differentiated treatment option for the treatment of obesity and chronic weight management as well as related metabolic disorders...Our first clinical study, LIBERATE-1, is anticipated to start in the fourth quarter of 2024 with results in 2025," said Adam Mendelsohn, Vivani President and CEO.
维瓦尼医疗公司总裁兼首席执行官亚当·门德尔森表示：“通过我们微型皮下埃塞那肽植入物在临床前观察到的肝脂肪减少，进一步证明了NanoPortal植入技术作为高度差异化的肥胖治疗选择以及相关代谢紊乱的巨大潜力……我们的第一项临床研究（LIBERATE-1）计划在2024年第四季度开始，结果将在2025年公布。”
Vivani's GLP-1 (exenatide) implant produced a sham-implant-adjusted liver fat reduction of 82% in an obese mouse model from a single administration with expected twice-yearly dosing.
维瓦尼的GLP-1（埃塞那肽）植入物在一次给药后预期每年两次服用，在肥胖小鼠模型中，相较于假植入物，肝脂肪减少82%。
These liver fat data are consistent with published results from similar investigations with semaglutide, the active pharmaceutical ingredient in Novo Nordisk A/S' (NYSE:NVO) Ozempic and Wegovy.
这些肝脂肪数据与诺和诺德（纽交所股票代码：NVO）的Ozempic和Wegovy中的人类胰高血糖素类似物semaglutide的已发表研究结果一致。
Previously reported results from this study in high-fat diet-induced obese mice demonstrated that Vivani's exenatide implant generated weight loss of approximately 20% compared to a sham implant control after a 28-day treatment duration, comparable to the weight loss observed in the semaglutide active control arm in the study.
此前在高脂饮食诱导的肥胖小鼠中进行的这项研究已经报告的结果表明，维瓦尼的埃塞那肽植入物与假植入物对照组相比，在28天的治疗期后，体重减轻约20%，与semaglutide的活性对照组中观察到的体重减轻相当。
The supratherapeutic doses provided for the exenatide implant (single administration delivering exenatide at ~530 nmol/kg/day) and semaglutide (weekly injections of ~2,700 nmol/kg/week) were selected to maximize the weight-loss potential of both exenatide and semaglutide.
选择超治疗剂量提供埃塞那肽植入物（单次给药每天达到埃塞那肽约530 nmol/kg）和semaglutide（每周注射约2700 nmol/kg/week）是为了最大限度发挥埃塞那肽和semaglutide的减重潜力。
In June, the FDA cleared Vivani's Investigational New Drug Application for NPM-119, paving the way for the commencement of the LIBERATE-1 Phase 1 trial.
6月份，FDA批准了Vivani的新药申请NPm-119的临床试验，为LIBERATE-1 Phase 1试验的开始铺平了道路。
Price Action: At the last check on Tuesday, VANI stock was trading higher by 7.32% at $1.32 premarketay.
价格走势：截至本周二最近一次检查，VANI股票在盘前交易中上涨7.32%，达到每股1.32美元。
- Opioid Settlement: Drug Distributors McKesson, Cencora, Cardinal Health To Pay $300M To Health Insurers.
- 阿片类药物和解：药品分销商麦克森、Cencora和卡地纳健康将向医疗保险公司支付30000万美元。
